Trials / Recruiting
RecruitingNCT07216560
First-in-human Study of 7MW4911 in GI Cancer
A Phase I/II Study of 7MW4911 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Advanced Colorectal Cancer and Other Advanced Gastrointestinal Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 7MW4911 | study drug |
Timeline
- Start date
- 2026-01-13
- Primary completion
- 2027-07-01
- Completion
- 2028-12-01
- First posted
- 2025-10-14
- Last updated
- 2026-01-15
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07216560. Inclusion in this directory is not an endorsement.